Loading...
01/11 04:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Basic financial performance and product development are positive, but the Q&A reveals concerns over market share loss in Asia, unclear management responses, and margin pressures. The raised EPS guidance and strong MySight growth are positives, but aggressive pricing and Clariti challenges pose risks. Overall, the sentiment is neutral, with a balanced mix of positive and negative factors.
Q3 consolidated revenues $1.06 billion, up 5.7% year-over-year or up 2% organically. Reasons for change: Reflects disciplined execution and operational excellence.
Non-GAAP earnings $1.10, up 15% year-over-year. Reasons for change: Strong margins and operational excellence.
Free cash flow $165 million. Reasons for change: Reflects robust operational performance.
Stock repurchase $52 million during the quarter. Reasons for change: Part of capital deployment strategy.
CooperVision revenues $718 million, reflecting 6.3% reported growth and 2.4% organic growth. Reasons for change: Decline in clariti globally and weakness in e-commerce in Asia Pac, offset by strong performance in EMEA.
EMEA regional growth 14% or 6% organically. Reasons for change: Strength across key markets and strong MyDAY activity.
Americas regional growth 2% or 3% organically. Reasons for change: Distributor channel inventory dynamics and clariti softness.
APAC regional growth Declined 5% organically. Reasons for change: Pressure from clariti and weakness in e-commerce channel.
MyDAY growth Double digits. Reasons for change: Resolved manufacturing constraints and increased fitting sets and trial lenses.
MiSight growth 23%. Reasons for change: Record-setting quarter in EMEA and increased fitting activity.
CooperSurgical revenues $342 million, up 4.5% or 2% organically. Reasons for change: Strength in genomics and consumables, offset by softness in fertility cycles in Asia Pac.
Fertility revenues $137 million, growing 6% or 3% organically. Reasons for change: Market share gains in EMEA and delayed capital purchases in Asia Pac.
Office and surgical revenues $205 million, up 3% year-over-year and 1% organically. Reasons for change: Growth in labor and delivery products and specialty surgical devices, offset by decline in PARAGARD.
Gross margin 67.3%, improved by 70 basis points. Reasons for change: Efficiency gains, mix, and positive foreign exchange.
Operating margin 26.1%. Reasons for change: Disciplined cost management and targeted SG&A leverage.
Net debt $2.35 billion. Reasons for change: Debt reduction efforts.
MyDAY product family: Achieved double-digit growth, with multifocal growing 20%. Manufacturing constraints resolved, enabling global rollout of fitting sets and trial lenses. New launches include MyDAY Energys in Europe (early fiscal 2026), MyDAY multifocal in major APAC markets, and MyDAY toric parameter expansion in multiple markets.
MiSight: Grew 23%, with record-setting performance in EMEA. Regulatory approval received for Japan launch (early 2026). Preparing for MyDAY MiSight launch in Europe and select APAC countries (first half of 2026).
clariti: Faced challenges due to customer shift to MyDAY. New launches like 3-add multifocal in the U.S. showed double-digit growth.
EMEA region: Achieved 14% growth (6% organic), becoming CooperVision's largest revenue region globally. Strong MyDAY fitting set and trial lens activity.
Asia Pacific region: Declined 5% organically due to clariti challenges and e-commerce weakness, particularly in China and Japan.
Operational efficiencies: Gross margin improved by 70 basis points to 67.3%. Operating margin expanded to 26.1%. Free cash flow was $165 million, with $52 million in stock repurchases.
R&D investments: Increased by 11%, focusing on product development and regulatory initiatives.
Fertility market outlook: Despite near-term headwinds, long-term optimism remains due to trends like delayed childbirth, increased access to treatment, and rising patient awareness.
Efficiency initiatives: Executing productivity and efficiency initiatives to position for strong 2026. Focus on IT upgrades and organizational infrastructure.
Revenue Performance: Revenues were lower than expected, driven by a decline in clariti globally, particularly in Asia Pacific, and weakness in the pure-play e-commerce segment in Asia Pacific, excluding Japan.
Product-Specific Challenges: Clariti orders were impacted by a shift in customer preference towards premium daily lenses like MyDAY, leading to a decline in clariti sales.
Regional Market Weakness: The Asia Pacific region, excluding Japan, experienced significant weakness in the pure-play e-commerce segment, mirroring earlier challenges in China.
Fertility Market Pressure: Fertility clinics are delaying capital purchases and installations due to conservative cash management, and there is ongoing softness in fertility cycles in Asia Pacific.
Inventory Dynamics: Distributor channel inventory dynamics in the Americas impacted growth, particularly for clariti and other products.
Tariff Impact: Tariffs are expected to pressure gross margins in fiscal 2026, despite mitigation strategies being implemented.
Economic and Market Uncertainty: There is potential risk from further inventory contraction and continued weakness in specific market segments, such as e-commerce in Asia Pacific.
Q4 2025 Revenue Guidance: Consolidated revenue guidance is $1.049 billion to $1.069 billion, representing 2% to 4% organic growth. CooperVision's revenue is expected to be in the range of $700 million to $713 million, up 2% to 4% organically, and CooperSurgical revenue is expected to be $350 million to $356 million, up 2% to 4% organically.
Fiscal 2026 Revenue Expectations: CooperVision expects to outpace the contact lens market and gain market share, driven by strong momentum with MyDAY, upcoming product launches, and recent contract wins. CooperSurgical anticipates improvements from a rebound in the fertility market as the Asia Pac region returns to growing cycles and fertility clinics resume investments.
Operating Margin Expansion: The company expects operating margin expansion in fiscal 2026, leveraging prior investment activity and a more efficient organization.
Free Cash Flow Projections: The company expects to generate approximately $2 billion in free cash flow over the next 3 fiscal years, supported by the completion of large CapEx investments, working capital initiatives, and disciplined cost control.
MyDAY Product Line Growth: The MyDAY product family is expected to drive significant growth, supported by the resolution of manufacturing constraints, global rollout of fitting sets and trial lenses, and new product launches such as MyDAY Energys in Europe (early fiscal 2026), MyDAY multifocal in major APAC markets, and MyDAY toric parameter expansion in multiple markets.
MiSight Expansion: MiSight is expected to continue its growth trajectory with upcoming launches in Japan (early 2026) and MyDAY MiSight across Europe and select Asia Pac countries in the first half of 2026. The company aims to achieve $100 million in MiSight sales this year.
Fertility Market Outlook: Despite near-term headwinds, the fertility market is expected to rebound in fiscal 2026, supported by trends such as delayed childbirth, increasing access to treatment, rising patient awareness, expanded benefits coverage, and continued innovation.
Contact Lens Market Trends: The contact lens market is expected to maintain mid-single-digit growth, driven by the transition to silicone hydrogel dailies, expanded adoption of toric and multifocal products, pricing, and growth in wearers.
Stock Repurchase: We repurchased $52 million of our stock during the quarter.
Share Repurchase Plan: We repurchased 724,000 shares of stock for $52.1 million, leaving approximately $164 million availability under our $1 billion board approved repurchase plan.
The earnings call indicates positive sentiment with strong product development, optimistic revenue guidance, and expected market share gains. The strategic plans for MyDAY and MiSight, along with anticipated operating margin expansion and free cash flow improvements, contribute to this outlook. Despite some gross margin pressure, the overall sentiment from the call, including analyst reactions, suggests a positive impact on stock price.
The earnings call presents a mixed outlook. Basic financial performance and product development are positive, but the Q&A reveals concerns over market share loss in Asia, unclear management responses, and margin pressures. The raised EPS guidance and strong MySight growth are positives, but aggressive pricing and Clariti challenges pose risks. Overall, the sentiment is neutral, with a balanced mix of positive and negative factors.
The earnings call reveals strong financial performance with a 6% revenue growth and a 14% EPS increase. The company maintains solid guidance and operational efficiency despite currency and tariff challenges. Share repurchases and a raised EPS guidance further indicate confidence. Although there are concerns in fertility and vision care markets, growth in myopia management and private label strategies remain robust. The Q&A section highlights management's optimism, especially with MiSight's growth, supporting a positive sentiment. Given the lack of market cap data, a moderate positive reaction (2% to 8%) is anticipated.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
